Kessler Topaz Meltzer & Check, LLP reminds investors of securities…

Kessler Topaz Meltzer & Check, LLP reminds investors of securities…

Facebook
Twitter
LinkedIn

RADNOR, Pa., April 7, 2023 (GLOBE NEWSWIRE) — The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is notifying investors that a securities class action lawsuit has been filed against Amgen Inc. (“Amgen”) in the United States District Court for the Southern District of New York. AMGN. The lawsuit alleges Amgen’s violations of federal securities laws, including omissions and fraudulent misrepresentations regarding the company’s business, operations and prospects. As a result of Amgen’s materially misleading public statements and omissions, investors in Amgen have suffered significant losses.

CLICK HERE TO SUBMIT YOUR AMGEN LOSSES. YOU CAN ALSO CLICK OR COPY AND PASTE THE FOLLOWING LINK INTO YOUR BROWSER: https://www.ktmc.com/new-cases/amgen-inc?utm_source=PR&utm_medium=link&utm_campaign=amgn&mktm=r

TO SEE OUR VIDEO PLEASE CLICK HERE

LIMIT FOR THE PLAINTIFF: MAY 12, 2023

COURSE PERIOD: JULY 29, 2020 TO APRIL 27, 2022

CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS:
Jonathan Naji, Esq. at (484) 270-1453 or via email to info@ktmc.com

Kessler Topaz is one of the world’s leading advocates for protecting the public from corporate fraud and other wrongdoing. Our securities fraud litigators are consistently recognized individually as leaders in the field, and our firm is feared and respected by both the defense and the Insurance Board. We are proud to have recovered billions of dollars for our clients and the classes of shareholders we represent.

AMGEN’S ALLEGED MISCONDUCT
On July 29, 2020, Amgen filed its 10-Q with the SEC, noting the company’s ongoing tax dispute with the U.S. government, but assuring investors that existing reserves are “adequate,” and not significant Provisions for related tax liabilities disclosed tax dispute.

Then, on August 3, 2021, Amgen announced for the first time massive outstanding tax liabilities filed by the IRS. The press release states that Amgen has received a notice of defects from…

[ad_2]

Source story

More to explorer